Evidence map›Paper›PMID 39487287›Full record

ArticleScientific reports2024

Design of an innovative aptasensor for the detection of chemotherapeutic drug Fludarabine phosphate.

Shamsa Alanazi, Amina Rhouati, Amani Chrouda, Dana Cialla-May, Jürgen Popp, Saddam Muthana, Majed Dasouki, Mohammed Zourob

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shamsa AlanaziDepartment of Chemistry, Alfaisal University, Al Zahrawi Street, Al Maather, Al Takhassusi Rd, Riyadh, 11355, Saudi Arabia.
Amina RhouatiDepartment of Chemistry, Alfaisal University, Al Zahrawi Street, Al Maather, Al Takhassusi Rd, Riyadh, 11355, Saudi Arabia.
Amani ChroudaDepartment of Chemistry, College of Science Al Zulfi, Majmaah University, Zulfi, Saudi Arabia.
Dana Cialla-MayInstitute of Physical Chemistry and Abbe Center of Photonics, Friedrich Schiller University, Jena, Germany.
Jürgen PoppInstitute of Physical Chemistry and Abbe Center of Photonics, Friedrich Schiller University, Jena, Germany.
Saddam MuthanaDepartment of Chemistry, Alfaisal University, Al Zahrawi Street, Al Maather, Al Takhassusi Rd, Riyadh, 11355, Saudi Arabia.
Majed DasoukiKing Faisal Specialist Hospital and Research Center, (KFSHRC), Takhussessi street, Riyadh, Saudi Arabia.
Mohammed ZourobDepartment of Chemistry, Alfaisal University, Al Zahrawi Street, Al Maather, Al Takhassusi Rd, Riyadh, 11355, Saudi Arabia. mzourob@alfaisal.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monitoring the concentration of Fludarabine phosphate, a standard chemotherapeutic drug widely used in cancer treatment, is vital for ensuring the drug's safety and effectiveness, tailoring treatments to individual needs, and consequently improving overall patient outcomes. Regarding the limitations of conventional techniques in terms of complexity, large time measurements, and a high cost, there is an urgent need to develop simple, rapid, and cost-effective devices. In this paper, we report the design of an aptasensor for the specific and selective detection of Fludarabine. Systematic evolution of ligands by exponential enrichment (SELEX) protocol was performed to select a specific aptamer for Fludarabine. Eleven rounds were carried out, and nine sequences were selected. Based on the dissociation constant (Kd), Ful-3, exhibiting the highest affinity (18.86 nM), was chosen and integrated into a simple electrochemical aptasensing platform for Fludarabine detection. Electrochemical results demonstrated good performance of the selected aptamer in detecting Fludarabine within the analytical range of 1 to 150 pg/mL and with LOD and LOQ in the order of 0.11 pg/mL (0.31 fM) and 0.39 pg/mL (1.06 fM), respectively. The developed platform also showed good selectivity against different analogous molecules and high applicability in serum-spiked samples, with recovery percentages ranging from 96.81 to 99.04%. Considering the encouraging results, this research presents an excellent alternative in terms of simplicity, stability, ease of use, reduction of sample volume, and low cost.

Indexed as

Aptamers, NucleotideBiosensing TechniquesVidarabine PhosphateAntineoplastic AgentsElectrochemical TechniquesHumansLimit of DetectionSELEX Aptamer TechniqueVidarabineAntineoplastic AgentsAptamers, Nucleotidefludarabinefludarabine phosphateVidarabineVidarabine PhosphateAnticancerAptamerBiosensorChemotherapeutic drugFludarabine phosphate

Identifiers

PMID39487287
PMCPMC11530680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.